Knowing stock market today at a glance

Why Did Ensysce Biosciences Plunge 20.98% After Patent Surge?

Mover TrackerThursday, Apr 24, 2025 4:41 am ET

1min read

On April 24, 2025, Ensysce Biosciences experienced a significant drop of 20.98% in pre-market trading, marking a notable shift in its stock performance.

Ensysce Biosciences has recently received a U.S. Patent Notice of Allowance for PF9001, a novel treatment for opioid use disorder (OUD). This patent covers both composition of matter and method of use claims for enzyme-cleavable methadone prodrugs, utilizing Ensysce's TAAP and MPAR technologies for abuse deterrence and overdose protection. The innovative medication aims to address limitations of current OUD treatments, particularly concerns over cardiac side effects, respiratory depression, and overdose risks.

The company's stock has seen significant volatility, with a surge of 96.26% to $3.67 on April 24, 2025, amidst heightened volatility. This surge was bolstered by recent patent news, which has validated Ensysce's abuse-deterrent technology in the valuable OUD market. The research, supported by the National Institute on Drug Abuse, aims to address limitations of current OUD treatments, particularly concerns over cardiac side effects, respiratory depression, and overdose risks.

Ensysce Biosciences has also announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office for the issuance of a patent entitled: Enzyme-Cleavable Methadone Prodrugs and Methods of Use Thereof. This patent covers both composition of matter and method of use claims, providing comprehensive coverage for their technology. The patent covers applications of Ensysce's dual technology platforms - TAAPTM (abuse deterrence) and MPAR® (overdose protection) - to methadone analogues for treating opioid use disorder (OUD).

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.